An antisense morpholino oligomer of formula (I): or a pharmaceutically acceptable salt thereof, where each Nu is a nucleobase which taken together forms a targeting sequence; T is selected from OH and a moiety of the formula: where each R 4 is independently C 1 -C 6 alkyl, and R 5 is selected from an electron pair and H, and R 6 is selected from OH, -N(R 7 )CH 2 C(O)NH 2 , and a moiety of the formula: where: R 7 is selected from H and C 1 -C 6 alkyl, and R 8 is selected from G, -C(O)-R 9 OH, acyl, trityl, and 4-methoxytrityl, where: R 9 is of the formula -(O-alkyl) y - wherein y is an integer from 3 to 10 and each of the y alkyl groups is independently selected from C 2 -C 6 alkyl; each instance of R 1 is -N(R 10 ) 2 R 11 wherein each R 10 is independently C 1 -C 6 alkyl, and R 11 is selected from an electron pair and H; R 2 is selected from H, G, acyl, trityl, 4-methoxytrityl, benzoyl, stearoyl, and a moiety of the formula: where L is selected from -C(O)(CH 2 ) 6 C(O)- and -C(O)(CH 2 ) 2 S 2 (CH 2 ) 2 C(O)-, and each R 12 is of the formula -(CH 2 ) 2 OC(O)N(R 14 ) 2 wherein each R 14 is of the formula -(CH 2 ) 6 NHC(=NH)NH 2 ; and R 3 is selected from an electron pair, H, and C 1 -C 6 alkyl, wherein G is a cell penetrating peptide ("CPP") and linker moiety selected from -C(O)(CH 2 ) 5 NH-CPP, -C(O)(CH 2 ) 2 NH-CPP, -C(O)(CH 2 ) 2 NHC(O)(CH 2 ) 5 NH-CPP, and -C(O)CH 2 NH-CPP, or G is of the formula: wherein the CPP is attached to the linker moiety by an amide bond at the CPP carboxy terminus, with the proviso that only one instance of G is present, wherein the targeting sequence is selected from: a) SEQ ID NO: 11 (TCA AGT TTT CC); b) SEQ ID NO: 12 (TCC TTT TAT TC); c) SEQ ID NO: 13 (CCA TCA AGT TT); d) SEQ ID NO: 14 (GGC AAT TCC AT); wherein X is 9, and thymine bases (T) may be uracil bases(U). where each Nu is a nucleobase which taken together forms a targeting sequence; T is selected from OH and a moiety of the formula: R 7 is selected from H and C 1 -C 6 alkyl, and R 8 is selected from G, -C(O)-R 9 OH, acyl, trityl, and 4-methoxytrityl, where: R 9 is of the formula -(O-alkyl) y - wherein y is an integer from 3 to 10 and each of the y alkyl groups is independently selected from C 2 -C 6 alkyl; each instance of R 1 is -N(R 10 ) 2 R 11 wherein each R 10 is independently C 1 -C 6 alkyl, and R 11 is selected from an electron pair and H; R 2 is selected from H, G, acyl, trityl, 4-methoxytrityl, benzoyl, stearoyl, and a moiety of the formula: where L is selected from -C(O)(CH 2 ) 6 C(O)- and -C(O)(CH 2 ) 2 S 2 (CH 2 ) 2 C(O)-, and each R 12 is of the formula -(CH 2 ) 2 OC(O)N(R 14 ) 2 wherein each R 14 is of the formula -(CH 2 ) 6 NHC(=NH)NH 2 ; and R 3 is selected from an electron pair, H, and C 1 -C 6 alkyl, wherein G is a cell penetrating peptide ("CPP") and linker moiety selected from -C(O)(CH 2 ) 5 NH-CPP, -C(O)(CH 2 ) 2 NH-CPP, -C(O)(CH 2 ) 2 NHC(O)(CH 2 ) 5 NH-CPP, and -C(O)CH 2 NH-CPP, or G is of the formula: wherein the CPP is attached to the linker moiety by an amide bond at the CPP carboxy terminus, with the proviso that only one instance of G is present, wherein the targeting sequence is selected from: a) SEQ ID NO: 11 (TCA AGT TTT CC); b) SEQ ID NO: 12 (TCC TTT TAT TC); c) SEQ ID NO: 13 (CCA TCA AGT TT); d) SEQ ID NO: 14 (GGC AAT TCC AT); a) SEQ ID NO: 11 (TCA AGT TTT CC); b) SEQ ID NO: 12 (TCC TTT TAT TC); c) SEQ ID NO: 13 (CCA TCA AGT TT); d) SEQ ID NO: 14 (GGC AAT TCC AT); wherein X is 9, and thymine bases (T) may be uracil bases(U). <EOS>